Abstract
Antipsychotic drugs are an essential component in the acute and long-term management of schizophrenia. Although most patients derive some benefit from currently available agents, many patients are left with residual psychopathology, particularly negative symptoms, as well as cognitive dysfunction and psychosocial and vocational disability. There is hope that new antipsychotic medications can improve overall effectiveness and that better knowledge transfer and integration of pharmacologic and psychosocial treatment strategies can also facilitate the achievement of optimum outcome.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have